Good morning, and welcome to the Altamira Therapeutics business update and full year 2023 earnings conference call. On today's call are Thomas Meyer, Altamira's Founder, Chairman, and Chief Executive Officer, and Covadonga Pañeda, Altamira's Chief Operating Officer. Earlier today, Altamira issued a news release with the full year 2023 financial results, as well as a comprehensive business update. The release is available on the company's website at www.altamiratherapeutics.com and has been filed with the SEC. During today's call, the company will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial, or business performance, or its strategies or expectations. Forward-looking statements are based on management's current expectations and beliefs, and involve significant risk and uncertainties that could cause actual results, development, and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of our clinical trials, the clinical utility of our product candidates, the timing or likelihood of regulatory filings and approvals, our intellectual property proposition, and our financial position, as well as those described in the Risk Factors section in our annual report on Form 20-F, and future filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the company's views only as of today and should not be relied upon as representing its views as of any subsequent date. While it may elect to update this forward-looking statement at some point in the future, it specifically disclaims any obligation to do so, even if its views change. With that, I will now hand the call over to Altamira Therapeutics CEO, Thomas Meyer. Please go ahead. Thank you, Razia. Hello, everyone, and thank you for joining our business update and full year 2023 earnings call. I will kick off the call by providing an overview of recent corporate developments, as well as an update on our strategy. Our COO, Covadonga Pañeda, will then discuss the progress in our new core business of RNA delivery. Finally, I will discuss our financials and outlook for 2024 before opening the call for any questions. Reflecting on where Altamira stood one year ago and where we are today, I'm pleased to say that we made great progress and emerged as a stronger and more focused company. We keep progressing with the RNA delivery business. More and more potential applications for our OligoPhore and SemaPhore nanoparticle technology are being identified, and we just recently concluded our second collaboration agreement with another exciting biotech company. Extrahepatic delivery of RNA and efficient intracellular release are hot topics in the industry. With the recent partial spin-off of our Bentrio legacy business, we took a significant first step on our journey towards becoming a fully focused RNA delivery company. We expect to complete the strategic repositioning of the company through partnering of our AM-125 legacy asset in 2024. Those legacy assets have substantial intrinsic value, and we just started to unlock that potential. We managed to streamline our cost structure and reduce cash burn very significantly. At the same time, we cleaned up our balance sheet by paying off all financial debt earlier than planned, and rebuilt shareholders' equity from a deficit to CHF 6.5 million, or more than $7.1 million. This puts us financially in a much stronger position. We are seeing great potential in the RNA space and are now much better positioned than one year ago to take advantage of these exciting opportunities. With this, I'm handing the call over to Covadonga Pañeda, our Chief Operating Officer, who will provide you with an update on our RNA delivery business. Cova? Thanks, Thomas, and good morning, everyone. Indeed, these are exciting times to work in the RNA space. Tremendous progress has been made over the past decades in science, research, and development, with the pace of discoveries and innovation increasing even more. Delivering RNA to target cells beyond the liver and releasing the RNA efficiently inside cells, however, have remained major challenges to date. This is where we come in with our peptide-based OligoPhore and SemaPhore nanoparticle platforms. The technology allows for extrahepatic RNA delivery as the nanoparticles distribute within the body to diseased tissues, in particular, to inflamed tissues in cancer and inflammatory or autoimmune diseases... Once inside target cells, the nanoparticles disassemble and release their RNA payload at substantially higher rates than lipid nanoparticles, the current industry standard. OligoPhore and SemaPhore have been validated across more than 15 distinct animal disease models, utilizing both siRNA and mRNA by various research groups worldwide, and we're excited to see the evidence continue to grow. In 2023, two in vivo studies performed by independent research groups using the SemaPhore platform show promising results for mRNA treatment in cancer and osteoarthritis. Upregulation of ZBTB46 expression resulted in an immunostimulatory tumor microenvironment and restricted tumor growth. This effect was significantly potentiated when combined with anti-PD-1 immune checkpoint inhibition. On the other hand, increase of DNMT3B expression resulted in reduced bone sclerosis, cartilage degeneration, synovitis, and pain sensitivity following meniscal injury. Another independent research group recently showed that insertion of our peptide into adeno-associated virus vectors significantly enhance cell transduction. Recombinant adeno-associated virus vectors are commonly used as carriers to introduce nucleic acid into cells for gene therapy. We are pursuing with the RNA delivery business, a pick and shovel strategy based on the licensing of our platform technology to partners in the biotech and pharma industry for use in their own RNA drug product development programs. The first of such collaborations have been set up. Heqet Therapeutics, a spin-off from King's College London, will test nanoparticles based on Altamira's OligoPhore platform and comprising certain non-coding RNAs in the regeneration of damaged heart tissue following myocardial infarction in animal models. Univercells Group will evaluate the use of the SemaPhore platform for the delivery of mRNA vaccines, increasing the effective amount of mRNA delivered to target cells with Altamira's technology, may allow for using lower mRNA doses and thus result in potentially more effective and efficient vaccines. We expect to enlarge, to engage in additional collaborations as we further develop the platform, generate additional data, and advance through IND-enabling studies. While working on our platforms, we are also pursuing two proprietary drug developmental programs. They are our flagship programs, which shall demonstrate the potential of the technology. At the same time, we believe that they represent attractive growth opportunities. We are developing AM-401 for the treatment of KRAS-driven cancers and AM-411 for the treatment of rheumatoid arthritis. We aim to advance both programs into an investigational new drug filing with the FDA in 2025, and to out-license them either following the IND or after our phase I clinical trial at the latest. The current focus is on the optimization of the formulation and process development for scaling up nanoparticle production. For the AM-401 program, Altamira filed a patent application with the United States Patent and Trademark Office to provide broad coverage of different KRAS mutations in cancer treatment, with nanoparticles comprising the OligoPhore platform and a single siRNA sequence that we call polyKRASmut. In vitro data confirmed the ability of polyKRASmut siRNA to knock down G12C, G12V, G12D, G12R, G12A, and A46T, which account for the majority of KRAS mutations in pancreatic, colorectal, and non-small cell lung cancer. I will now turn the call back to Thomas. Thanks, Cova. Let me discuss now our two main legacy assets, the Bentrio drug-free nasal spray for allergy, and our AM-125 betahistine nasal spray for vertigo and other disorders of the central nervous system. In November of last year, we announced a partial spin-off of our Bentrio business as an important first step in our strategic pivot towards RNA delivery. As a reminder, we sold a 51% stake in our subsidiary, Altamira Medica AG, to a Swiss private equity investor for a cash consideration of CHF 2.04 million, or approximately $2.3 million. Apart from the raise of non-dilutive cash, the transaction generated a financial gain of CHF 5.2 million, or close to $6 million, and will result in a lowering of operating expenses. Altamira will be entitled to receive 25% of any future licensing income of Medica, and also of Medica's value appreciation in case of a sale, which captures an additional share of the business upside potential.... We consider this upside potential to be substantial. In clinical trials, Bentrio showed great efficacy in alleviating the main symptoms of allergic rhinitis, hay fever, and improving health-related quality of life. All of this without containing any active pharmaceutical ingredient. This allows for a unique positioning of the product as an alternative to medicated nasal sprays, or in combination with oral treatments such as antihistamines. We expect sales to grow significantly from 2024 onwards, primarily driven by the launch of Bentrio through distributors in additional countries. For China, one of the largest markets worldwide, we already have a collaboration. It is with Nuance Pharma, which began in 2022. Nuance is currently distributing the product successfully in Hong Kong and is aiming for market approval in mainland China and South Korea later this year. Altamira Medica will initially supply Bentrio to Nuance and may receive development and commercial milestones of up to $3 million and up to $19.5 million, respectively. Once Nuance assumes local production of Bentrio, it will pay to Altamira a staggered royalty on net sales at a high single- to low double-digit percentage. In Scandinavia, our partner, Pharma Nordic, just launched the product in Q1 2024, and we look forward to a successful development there as well. For other key markets, notably the U.S., the world's largest OTC consumer health market, in Europe and elsewhere, discussions and negotiations with interested parties are ongoing. Bentrio was cleared by the FDA for marketing. However, it's not being marketed in the U.S. yet, ending the partnering of the product. We do expect major news flow here in 2024. Overall, we're confident to see our stake in Altamira Medica generate a growing revenue stream and result in significant value appreciation. Following this first step in the strategic repositioning of our company, we expect to take the next one in 2024 by partnering our inner ear assets. Partnering discussions are most advanced regarding AM-125, a patented nasal spray for the treatment of acute vestibular syndrome, or briefly, AVS, a very frequent type of dizziness. This product has been developed to help acutely dizzy patients to get back on their feet more quickly. The drug product is a reformulation of betahistine, a histamine analog, which in the traditional oral formulation, is standard of care treatment for vertigo in many countries around the world. A phase II trial in Europe demonstrated that a four-week treatment course with AM-125 in AVS patients was well tolerated and helped to accelerate vestibular compensation, enabling patients to regain balance and recover faster. In the U.S., where oral betahistine exceptionally has not been marketed for decades and no comparable product exists, Altamira received in summer 2023, IND clearance from the FDA. To date, we have invested about $18 million in the program. There is one important aspect to AM-125. Since betahistine is a histamine analog, AM-125 may have clinical utility in other central nervous system disorders known for the involvement of histamine. It is known that histamine plays an important role in the regulation of a wide range of behavioral and physiological functions, such as appetite, drinking, sleep, wakefulness, learning, attention, and memory. Studies by independent research groups have shown clinical benefits of betahistine in the treatment of ADHD, cognitive function in dementia, memory loss, and antipsychotic-induced weight gain, among others. And histamine is a target in narcolepsy, Prader-Willi syndrome, for which we have an orphan drug designation, or Tourette syndrome. Therefore, we believe that our AM-125 offers quite some potential in partnering for vertigo, but also beyond, and especially in the U.S. market, where there is no oral betahistine available. It is important to note that despite its significant potential, the AM-125 asset currently carries zero value on our balance sheet. Any proceeds derived from partnering would therefore have a direct and positive impact on our bottom line. Now, turning to our financials. Before reviewing our financials for the full year 2023, I would like to note that the financial statements are presented in Swiss francs. To help you with interpreting the financials, please note that 1 CHF is worth approximately $1.1. Further, I need to highlight that the 2022 income statement has been revised retrospectively due to the partial divestiture of the Bentrio business. The Bentrio activities are reported now as so-called discontinued operations. Continuing operations, therefore, comprise the RNA delivery development programs, as well as those related to AM-125. In 2023, we made great progress in aligning our cost structure with the strategic pivot to the RNA delivery business. Total operating loss from continuing operations decreased from CHF 18 million in 2022 to CHF 5.9 million in 2023. Research and development expenses were CHF 3 million in 2023 versus CHF 14.6 million in 2022. Excluding a one-time non-cash write-off impairment of capitalized development expenditures for the AM-125 project based on impairment testing under IFRS, as just mentioned, these, this program has zero value currently on the balance sheet. Research and development expenses rose about 33% from 2022. General and administrative expenses decreased from CHF 3.4 million - CHF 3.1 million. This- Ladies and gentlemen, please continue to stand by. The conference will resume shortly. Thank you. Once again, ladies and gentlemen, please continue to stand by. Your conference will resume shortly. Thank you for your patience. Once again, ladies and gentlemen, please continue to stand by. Your conference will resume shortly. Thank you very much for your patience. ... Hello, Thomas, can you hear us? Yes, I can hear you. Please, please continue. Thank you. Okay. Where was I interrupted? I think you were on slide 17. Okay. So hello, I'm back. So apologies here for the interruption. We lost connection. I start again with slide 17. So shareholders? Okay. So can you hear me? Yes, we can hear you, sir. Okay. Seems to be a difficult connection. Apologies. All right, so shareholders' equity swung from a deficit of CHF 8.3 million at the end of 2022, to a + CHF 6.5 million by the end of 2023, which represents an improvement of CHF 14.8 million. This reflects primarily equity raises via the equity line with Lincoln Park, the ATM program with H.C. Wainwright, the amortization of the five-year convertible loan, which was completed ahead of time, as well as warrant exercises. On top of this, we raised non-dilutive capital through the partial venture divestiture. Total liabilities could be reduced from CHF 14.6 million at year-end 2022, to CHF 1.2 million at year-end 2023. At this point, no more financial debt was outstanding. One year before, financial debt stood at CHF 5.9 million. In terms of cash flow, while cash used in operations rose from CHF 8.7 million in 2022 to CHF 11.5 million, primarily due to the normalization of net working capital. Investing activities provided CHF 1.4 million, reflecting mainly the cash inflow from the venture transaction. This compares to a cash drain of CHF 2.1 million in 2022. The aforementioned financing activities provided CHF 10.6 million in 2023 versus CHF 9.8 million in 2022. Cash and cash equivalents on November 31st, 2023, totaled CHF 0.62 million, compared with CHF 15,000 the year before. Altamira expects its regular total funding requirements for operations and financial obligations in 2024 to be in the range of $6.5 million-$7.5 million. That is without any potential proceeds from partnering. During the first quarter of 2024, the company raised about $2 million from share issuance under the at-the-market program with H.C. Wainwright and the equity line with Lincoln Park Capital. Altamira expects to cover its remaining funding needs through the partnering of its legacy assets and/or the sale of equity or convertible debt securities. With this, let me conclude with a brief summary and some perspectives. We emerged from 2023 in much better shape than we entered it, which is good, especially in view of the pretty strong headwinds that the biotech sector has been facing until quite recently. It has been a challenging period for many of our investors, especially those of us who have been around for some time. The partnering of our legacy assets has admittedly taken longer than expected, but now we have locked down that venture deal, and we're working towards the completion of the process with the aim of partnering AM-125 this year. In addition, with our OligoPhore SemaPhore platforms, we have a very exciting technology for a very exciting field in human medicine. The platform is very versatile and can be scaled across many different uses. The picks and shovels model means that cash outflows are smaller and cash inflows come earlier. Over the coming years, we anticipate entering into a growing number of collaborations based on our development programs and business development activities. Last but not least, we have a great, highly motivated team in place to move our RNA delivery projects forward. All of this makes me confident about the future, and I recently added some shares to my holdings. Looking forward, 2024 promises to be an interesting, exciting year with multiple milestone events and news flow. I would now like to turn the call back to the operator to open the lines for questions. Thank you, sir. As a reminder to ask a question, please press star one and one on your telephone and wait for your name to be announced.... To withdraw your question, please press star one and one again. Once again, please press star one and one on your telephone and wait for your name to be announced. Please stand by while we compile the Q&A roster. This will take a few moments. Thank you. Once again, please press star one and one if you have any questions or comments. Thank you. We are now going to proceed with our first question. Hello, Hunter, can you hear us? Your line is open. Please ask your question. Yes. Yes, I can hear you. So, firstly, congratulations on the results and all the recent progress. So given the shift towards the pick and shovels business model, what criteria is the company using to select and prioritize collaborations or licensing agreements for its RNA delivery platforms? And additionally, how does the company plan to leverage its flagship programs to demonstrate the platform's versatility and attract potential partners? Yeah, good morning, Hunter, and thank you very much. Yeah, so we see here, let's say the partnering evolve in probably two steps. So the first step currently is a more exploratory approach. So we have here a platform that has already shown its utility in under quite a few settings. And the Univercells collaboration is one example here. This is something that we have not been pursuing so far, that is vaccines, mRNA. This came up here during the last year. It's something we feel is exciting, but of course, it has something still exploratory in nature. We have the Heqet collaboration, which is a group that has achieved quite some success with regeneration, cardiac, regeneration. But they were in need of finding a, an appropriate and adequate, delivery, vehicle. And so these are things that come up during business development contacts. Some of these companies approach us. We are pretty much open-minded here. However, it's clear we want to do only things where we see, okay, this can lead, to a product at, at some point. And, this is how we, prioritize, here, these, inquiries. Now, we are ourselves still adding, data, on the platform. The package keeps growing, and that's why I'm talking about two steps. So here, first step is still a little bit on the exploratory side, but as we will have more and more data, we will talk about a more and more comprehensive package, of data that we can offer. And that's when we then expect to see also an increase in size, in magnitude here, in scope of these collaborations. So that's the way we see that. So yes, I mean, we are open, but clearly focus here is on programs that make sense scientifically and economically. And we will evolve here as also the scope and the content of our package is evolving. In terms of the second question about the flagship programs, so maybe Cova, that's one for you. So with, with the flagship programs, we're hoping to show what our platform can actually deliver within two of the main areas where we see that the SemaPhore and OligoPhore can be of advantage, and that is oncology and inflammatory diseases. So, the data that we will generate, we hope will enable us not only to move these assets into clinical development, but also to show our potential collaborators what the platform can achieve in these areas. Great. Thank you very much for the detailed answer. And then, going back to the legacy programs, do you have any idea of sort of the timeline or milestones for that? And I guess I'm trying to just get more color on how it fits into the RNA program. It may be difficult to, you know, discuss timing or milestones, but whatever you can mention on that. ... Yes, indeed, that's a little bit challenging. I mean, we have the two main legacy assets, and so Bentrio here, we did the first step, and what we now expect to happen is, through the partnering here for key markets, North America, Europe, and a couple of other markets, that Medica, so the company that we spun off partially, that they will be able here to engage in partnerships, one or several partnerships in 2024. So timing, still a bit open, but, I mean, it has been a while that we have been going through these discussions. We have some parties that could actually be a great fit here for the business in terms of distribution, marketing, power, and capacity. So, this is something that we expect that to happen here, as we progress through 2024. Now, as a shareholder in Medica, we'll benefit from that, but, you know, we also have this, 25% share of any licensing stream that will flow to Medica. So that's something that will then actually flow through to Altamira Therapeutics. We have also the Nuance collaboration, I mean, which is already in place, which started in 2022. So, upon mainland China giving the approval for Bentrio in China, we will also receive some milestone share of that. So that's also in the making. Now, AM-125, as mentioned here, discussions have been going on for some time. We have here a number of interested parties. At this point, it's still open whether we will finally go for a more global deal or a set of regional collaborations. We believe that the U.S. is a very attractive market for this. Here, we have the opportunity actually to do either vertigo, that's what betahistine has been developed for, or to do some other indication that can be a rare disease, that can be something that is much more frequent. And the nice thing here is that, okay, this is really a wide spot in the U.S. betahistine, oral betahistine is not available, so here there is much more flexibility than in other countries. However, in other countries as well, betahistine is well-established in vertigo. That's the focus, and here, we have a $450 million market for oral. As of today, we expect that 125 could take a nice slice out of this. Now, the difference between, let's say, U.S. and rest of world, that means, or this explains why we have this question, whether it's going to be more a global type of deal, or whether we may have more a regional type of transaction, because we have these differences in market. But overall, I mean, things are progressing, and we also expect that here, something significant will happen in 2024. I hope this answers your question, even without being fully specific about timelines. No, absolutely. That's, that's very useful and, and it was great additional color. So, thank you for taking my questions, and I appreciate the update. You're welcome. Thank you. As a reminder, to ask a question, please press star one and one on your telephone and wait for your name to be announced. To withdraw your question, please press star one and one again. Thank you. We are now going to proceed with our next question. And the question comes from the line of Andrew Scott from 395 Group. Please ask your question. Your line is open. Great. Good morning, afternoon, Thomas. A lot of the questions that I had were answered in the prior statement, but you've really done a good job in turning the company around. I see a lot of the progress that you're doing on the RNA platform right now. I thought the questions about potential and criteria for other collaborations, you've picked up two so far. I imagine you're talking to a variety of other people. So the RNA platform's got some pretty good traction. We got the update on Bentrio, and then, as far as AM-125, I know that's been the primary asset and you've put a lot of money into it, but do you have any idea on what a potential partnering or out-licensing of the asset would look like? Are you looking for $1 million? Are you looking for $5 million? Obviously, as much as you can get, because you put a lot of money into it. But can you give us an idea on, you know, how you're looking to move that asset on and build additional value for the company? Really great turnaround, and positive shareholder equity year-over-year too. So congrats. Okay. Thank you, Andrew. Yeah, indeed, there is a lot of value in AM-125. As I mentioned, we have invested $18.18 million over the years into this. I think what is particular about this product is really it's relatively low risk in the sense that it's a reformulation, a nasal spray. It has much better bioavailability than the oral form, and it's patented. I mean, this is all attractive, obviously, for pharma biotech companies because it's a much different profile. And what is also very unique is that, well, you have here a pretty significant drug that is literally marketed around the world in more than 110 countries, but in the U.S., it's not on the market. I mean, it was pulled from the market, not for safety reasons, in the early 1970s, and it was never reintroduced. Well, after a while, nobody had any patent to protect it, but now, okay, we have a formulation that actually works better than oral, and it's patented. It's patented up to 2038. Now, if you take this risk profile, if you take then the fact that there is an existing market, and you take the fact that there is IP behind it, then, of course, you, you can get here some pretty interesting scenarios. And one scenario, as already mentioned, that is okay, U.S., well, can be different things, different indications that, that are developed. I mean, I mentioned, for example, Prader-Willi syndrome, which is a rare disease, pediatric rare disease. Here we have had discussions with patient organizations, so there is definitely a need for this. Could be an interesting development, but it could also be a very interesting development for other CNS disorders. There are clinical data on ADHD, for example, but also vertigo. U.S. doctors, they tell us, "We want to see that product approved." So that's one value pot, so to speak, and ex-U.S., well, you have that existing market, and it's essentially you can or we expect this to be marketed at a premium pricing. Now, as you can already feel and sense, Andrew, I'm trying to avoid giving you here very concrete guidance indications on how a deal or how deals could look like. I mean, let's put it that way. Of course, we see here quite some upside. We have a structure process that is ongoing, so we have here some external help. While we will seek to find the best possible partner or partners for this program to unlock the value that is embedded in this product. I hope you bear with me that at this point, I cannot be more specific than that. I understand, Thomas. I'm good. But congrats. I am seeing a lot of other publications about betahistine, so I imagine that asset's gonna get much more interesting. But congrats again on a great turnaround in the year. Okay. Thank you. Appreciate it. Thank you. As there are no further questions at this time, I will now turn the call back to management for any concluding remarks. Thank you. Okay. Thank you. I believe we have covered all the highlights thoroughly today. Apologies again for the technical issues. I will simply thank everyone for attending this morning's call, and for your good questions, and we'll wish you a terrific day ahead. Thank you. Take care. Bye-bye. Ladies and gentlemen, this concludes today's conference call. Thank you all for participating. You may now disconnect your lines. Thank you.